250 related articles for article (PubMed ID: 33598420)
1. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
Front Oncol; 2020; 10():571308. PubMed ID: 33598420
[TBL] [Abstract][Full Text] [Related]
2. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
7. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
8. Treatment-induced neuroendocrine prostate cancer and
Wishahi M
World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
[TBL] [Abstract][Full Text] [Related]
9. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
10. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
Beltran H; Jendrisak A; Landers M; Mosquera JM; Kossai M; Louw J; Krupa R; Graf RP; Schreiber NA; Nanus DM; Tagawa ST; Marrinucci D; Dittamore R; Scher HI
Clin Cancer Res; 2016 Mar; 22(6):1510-9. PubMed ID: 26671992
[TBL] [Abstract][Full Text] [Related]
11. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
[TBL] [Abstract][Full Text] [Related]
14. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
15. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G
Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H; Nakagawa R; Makino T; Kadomoto S; Yaegashi H; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Anticancer Res; 2022 Apr; 42(4):2167-2176. PubMed ID: 35347041
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
20. CDHu40: a novel marker gene set of neuroendocrine prostate cancer (NEPC).
Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
bioRxiv; 2024 Mar; ():. PubMed ID: 38585861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
